Autoradiographic evidence that (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB) displays in vivo selectivity for the muscarinic m2 subtype

被引:9
作者
Boulay, SF
Sood, VK
Rayeq, MR
Zeeberg, BR
Eckelman, WC
机构
[1] GEORGE WASHINGTON UNIV,MED CTR,DEPT RADIOL,SECT RADIOPHARMACEUT CHEM,WASHINGTON,DC 20037
[2] NIH,PET DEPT,CTR CLIN,BETHESDA,MD 20892
来源
NUCLEAR MEDICINE AND BIOLOGY | 1996年 / 23卷 / 07期
关键词
pharmacokinetic modeling; emission tomographic neuroreceptor quantitation; radioiodinated; (R; S)4IQNB; S)-FMeQNB;
D O I
10.1016/S0969-8051(96)00121-7
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Alzheimer's disease (AD) involves selective loss of muscarinic m2, but not m1, subtype neuroreceptors in cortical and hippocampal regions of the human brain. Until recently, emission tomographic study of the loss of m2 receptors in AD has been limited by the absence of available m2 selective radioligands that can penetrate the blood brain barrier. We now demonstrate the in vivo m2 selectivity of a fluorinated derivative of QNB, (R)-3-quinuclidinyl (S)-4-fluoromethylbenzilate ((R,S)-FMeQNB), by studying autoradiographically the in vivo inhibition of radioiodinated (R)-3-quinuclidinyl (S)-4-iodobenzilate ((R,S)-[I-125]IQNB) binding by unlabelled (R,S)-FMeQNB. In the absence of (R,S)-FMeQNB, (R,S)-[I-125]IQNB labels brain regions in proportion to the total muscarinic receptor concentration; in the presence of 75 nmol of (R,S)-FMeQNB, (R,S)-[I-125]IQNB labelling in those brain regions containing predominantly m2 subtype is reduced to background levels. We conclude that (R,S)-FMeQNB is m2 selective in vivo, and that (R,S)-[F-18]FMeQNB may be of potential use in positron emission tomographic (PET) study of the loss of m2 receptors in AD. Copyright (C) Elsevier Science Inc.
引用
收藏
页码:889 / 896
页数:8
相关论文
共 41 条
[1]   DIFFERENTIAL ALTERATION OF VARIOUS CHOLINERGIC MARKERS IN CORTICAL AND SUBCORTICAL REGIONS OF HUMAN-BRAIN IN ALZHEIMERS-DISEASE [J].
ARAUJO, DM ;
LAPCHAK, PA ;
ROBITAILLE, Y ;
GAUTHIER, S ;
QUIRION, R .
JOURNAL OF NEUROCHEMISTRY, 1988, 50 (06) :1914-1923
[2]   COMPARATIVE ALTERATIONS OF NICOTINIC AND MUSCARINIC BINDING-SITES IN ALZHEIMERS AND PARKINSONS DISEASES [J].
AUBERT, I ;
ARAUJO, DM ;
CECYRE, D ;
ROBITAILLE, Y ;
GAUTHIER, S ;
QUIRION, R .
JOURNAL OF NEUROCHEMISTRY, 1992, 58 (02) :529-541
[3]  
Boulay SF, 1995, RECEPTOR, V5, P207
[4]   Autoradiographic evidence that 3-quinuclidinyl-4-fluorobenzilate (FQNB) displays in vivo selectivity for the m2 subtype [J].
Boulay, SF ;
Dood, VK ;
Rayeq, MR ;
Cohen, VI ;
Zeeberg, BR ;
Reba, RC .
NEUROIMAGE, 1996, 3 (01) :35-39
[5]   AUTORADIOGRAPHIC EVIDENCE THAT QUINUCLIDINYL 4-(BROMOPHENYL)-2-THIENYLGLYCOLATE (QBPTG) DISPLAYS IN-VIVO SELECTIVITY FOR THE MUSCARINIC M2 SUBTYPE [J].
BOULAY, SF ;
SOOD, VK ;
RAYEQ, MR ;
MCREE, RC ;
COHEN, EI ;
COHEN, VI ;
ZEEBERG, BR ;
REBA, RC .
NEUROIMAGE, 1995, 2 (03) :209-213
[6]  
COHEN VI, 1989, J PHARM SCI, V78, P833
[7]  
FLYNN DD, 1995, J NEUROCHEM, V64, P1888
[8]   INVIVO DISSOCIATION KINETICS OF [H-3] QUINUCLIDINYL BENZILATE - RELATIONSHIP TO MUSCARINIC RECEPTOR CONCENTRATION AND INVITRO KINETICS [J].
GIBSON, RE ;
ZEEBERG, BR ;
MELOGRANA, JM ;
WANG, TF ;
RUCH, J ;
BRAUN, A ;
REBA, RC .
BRAIN RESEARCH, 1991, 553 (01) :110-116
[9]  
GIBSON RE, 1984, J NUCL MED, V25, P214
[10]   [H-3] QNB DISPLAYS IN-VIVO SELECTIVITY FOR THE M2 SUBTYPE [J].
GITLER, MS ;
DELACRUZ, R ;
ZEEBERG, BR ;
REBA, RC .
LIFE SCIENCES, 1994, 55 (19) :1493-1508